SIOPEN

  • International Society of Paediatric Oncology Europe Neuroblastoma

G-CSF in induction for high risk disease

In the HR-NBL/SIOPEN study, 239 patients with neuroblastoma in 16 countries were randomly assigned to receive or not receive prophylactic G-CSF during induction chemotherapy with rapid COJEC. The results showed that patients receiving G-CSF had significantly fewer episodes of febrile neutropenia, days in hospital and days receiving antibiotics. Severe weight loss was also significantly less common in this group receiving G-CSF. There was no change in the effectiveness of the chemotherapy. As a result of this study, all patients now receive prophylactic G-CSF during induction chemotherapy with rapid COJEC.

Link to abstract on PubMed

Link to full text of article in Journal of Clinical Oncology

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information

SIOPEN

SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.